Transdermal delivery system for anti-emetic medication
First Claim
Patent Images
1. A system for transdermal delivery of a hydrophilic anti-emetic agent from a pharmaceutical composition comprising:
- an apparatus for facilitating transdermal delivery of a hydrophilic anti-emetic agent through skin of a subject, said apparatus comprises;
(a) an electrode cartridge comprising at least one electrode; and
(b) a main unit comprising a control unit which is adapted to apply electrical energy to the electrode when the electrode is in vicinity of the skin, enabling ablation of stratum corneum in an area beneath the electrode, thereby generating at least one micro-channel in an area on the skin of the subject;
and a separate patch that does not receive electrical energy from the apparatus, the patch is adapted to be applied to the area on the skin after the at least one microchannel is generated, said patch comprising at least one hydrophilic layer comprising a hydrophilic polymer and a therapeutically effective amount of the hydrophilic anti-emetic agent in a pharmaceutical composition, devoid of permeation enhancers.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides a transdermal delivery system for hydrophilic anti-emetic agents and methods of using thereof. The system includes an anti-emetic hydrophilic adhesive composition of a hydrophilic polymer and hydrophilic anti-emetic agent, a patch containing at least one hydrophilic layer of the composition, and an apparatus that generates hydrophilic micro-channels in skin of a subject using the patch or composition. The system preferably avoids the use of penetration enhancers and is particularly useful for transdermal delivery of hydrophilic anti-emetic agents.
-
Citations
33 Claims
-
1. A system for transdermal delivery of a hydrophilic anti-emetic agent from a pharmaceutical composition comprising:
-
an apparatus for facilitating transdermal delivery of a hydrophilic anti-emetic agent through skin of a subject, said apparatus comprises; (a) an electrode cartridge comprising at least one electrode; and (b) a main unit comprising a control unit which is adapted to apply electrical energy to the electrode when the electrode is in vicinity of the skin, enabling ablation of stratum corneum in an area beneath the electrode, thereby generating at least one micro-channel in an area on the skin of the subject; and a separate patch that does not receive electrical energy from the apparatus, the patch is adapted to be applied to the area on the skin after the at least one microchannel is generated, said patch comprising at least one hydrophilic layer comprising a hydrophilic polymer and a therapeutically effective amount of the hydrophilic anti-emetic agent in a pharmaceutical composition, devoid of permeation enhancers. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
-
11. A method for transdermal administration of a hydrophilic anti-emetic agent comprising:
- generating at least one micro-channel in an area of skin of a subject; and
affixing a patch to the area of skin where the at least one micro-channel is present, the patch comprises at least one hydrophilic layer comprising a hydrophilic polymer and a therapeutically effective amount of a hydrophilic anti-emetic agent in a pharmaceutical composition, devoid of permeation enhancers. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
- generating at least one micro-channel in an area of skin of a subject; and
-
22. A method of transdermal administration of a hydrophilic anti-emetic agent comprising:
- generating at least one micro-channel in an area of the skin of a subject; and
thereafter affixing a patch to the area of skin of the subject where the at least one micro-channel is present, wherein the patch comprises at least one hydrophilic layer comprising a hydrophilic polymer and a therapeutically effective amount of a hydrophilic anti-emetic agent in a pharmaceutical composition, devoid of permeation enhancers, the hydrophilic anti-emetic agent capable of diffusing through the at least one micro-channel to achieve a therapeutically effective serum concentration of at least 1 ng/ml in the subject. - View Dependent Claims (23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
- generating at least one micro-channel in an area of the skin of a subject; and
Specification